Self-Funded Health Insurance: International Provider Directory
US commercial hospital prices have remained at or above 254% of Medicare since 2018 (RAND Corporation, Round 5.1, 2024). Approximately half of US metropolitan areas are served by one or two health systems for all inpatient commercial care (Peterson-KFF Health System Tracker). Published procedure pricing from JCI or equivalent nationally accredited international hospitals is available as a plan resource through a directory and booking-infrastructure layer.
No eligibility file exchange, no technical integration, and no data flows between the marketplace and the plan. The platform collects an auto-assigned ID, an email address, and a procedure name. Providers fund the marketplace through commissions on completed treatment.
US Commercial Pricing: Market Concentration and Cost Dynamics
US commercial hospital pricing is structurally determined by market concentration rather than clinical outcomes or operational cost. Commercial prices have remained at or above 254% of Medicare since 2018, according to the RAND Corporation's Hospital Price Transparency Study (opens in new tab) (Round 5.1, May 2024). The Peterson-KFF Health System Tracker documents that approximately half of US metropolitan areas are served by one or two health systems for all inpatient commercial hospital care. This market concentration is the structural explanation for the RAND figure: hospitals operating in concentrated markets face limited competitive pressure on price.
The top 5% of high-cost claimants account for 49.7% of total healthcare spending ( AHRQ Medical Expenditure Panel Survey, 2025 (opens in new tab)). Million-dollar claims per million covered employees increased 61% between 2020 and 2024 ( Sun Life, 2025 (opens in new tab)). The procedure categories driving these claims (cardiac, spinal, orthopaedic, bariatric) are the same categories where international pricing differentials at JCI-accredited facilities are 40-80%.
Domestic cost containment mechanisms (reference-based pricing, narrow networks, bundled payment arrangements) operate within concentrated local markets. Each tool generates friction: reference-based pricing creates provider disputes, narrow networks restrict employee choice, and bundled payments reduce unit cost variability without addressing base pricing levels. International pricing from JCI-accredited facilities introduces a reference point from a structurally different market where providers compete on published pricing.
| Procedure | US Commercial Price | International Price Examples |
|---|---|---|
| Coronary Artery Bypass (CABG) | $57,240 - $89,094 | India $7,900 | Spain $10,734 | Turkey $13,900 |
| Hip Replacement (Total) | $28,167 - $50,564 | India $7,200 | Spain $6,623 | Turkey $13,900 |
| Spinal Fusion (Single Level) | $80,000 - $150,000 | Thailand $9,500 | India $10,300 | Mexico $15,400 |
International Pricing Infrastructure: How the Marketplace Functions
Sylk Health operates as a directory and booking-infrastructure layer. JCI or equivalent nationally accredited international providers list procedures with published pricing, estimated wait times, and consultation availability. Plan members browse 1,954 procedures, compare pricing across providers and countries, and book consultations directly with the facility they select. The member speaks to the hospital upon booking. There is no clinical intermediary, no care coordination, and no episode management.
The function is comparable to domestic price transparency tools (Healthcare Bluebook, Turquoise Health) applied to international JCI-accredited facilities. Most platforms in international care require prospective patients to call, fill out a form, or request a quote. The Sylk Health marketplace publishes the pricing before any interaction occurs.
Sylk Health doesn't sit inside the clinical relationship. It doesn't arrange travel, hold member funds, issue binding quotes, run second-opinion services, or make provider recommendations. It doesn't manage pre-operative workups or post-operative follow-up. Members see a directory of options with published prices. They choose.
The Listing Threshold: JCI or Equivalent National Accreditation
JCI accreditation is the primary credentialing filter. In markets with rigorous national systems, such as China's 3A tertiary hospital classification, Sylk Health also lists providers meeting equivalent national standards. No proprietary quality scores. No editorial rankings. No featured placements.
Data Collection and HIPAA Posture
The platform's data collection is limited to three fields per user: an auto-assigned ID, an email address, and a procedure name. No data is exchanged between the plan and Sylk Health. No member-identifiable data flows to the marketplace from the plan sponsor.
Data Collection Scope
Sylk Health doesn't receive member rosters, eligibility files, claims data, demographic information, or any data that identifies an individual as a member of a specific plan. When a person uses the marketplace, the only data retained is:
- An auto-assigned ID string (not derived from any external identifier)
- The email address the user provided
- The procedure the user requested a consultation for
That's the complete data record. No names. No dates of birth. No insurance IDs. No diagnosis codes. No medical history.
Why No BAA Is Expected to Be Required
A BAA is required under HIPAA when a vendor creates, receives, maintains, or transmits protected health information on behalf of a covered entity. Sylk Health's system is designed to minimise data collection to an auto-assigned ID, an email address, and a procedure name. This minimal footprint is intended to fall below the PHI threshold. Plan sponsors should confirm with their own privacy counsel.
Comparison to Typical Vendor Data Requirements
| Data Element | Typical Vendor | Sylk Health |
|---|---|---|
| Member roster / eligibility file | Required | Not collected |
| Member names, DOB, SSN | Required | Not collected |
| Insurance ID / group number | Required | Not collected |
| Diagnosis / ICD codes | Often required | Not collected |
| Claims data | Often exchanged | Not collected |
| PHI of any kind | Present in system | Minimal by design |
| BAA required | Yes | Not expected to be required |
| HIPAA security review | Required | Minimal exposure |
| Ongoing compliance monitoring | Required | Minimal exposure |
Typical health plan vendor implementation involves BAA negotiation, security review, eligibility file integration, data-flow mapping, and ongoing compliance monitoring. The marketplace model doesn't require these steps because no member-identifiable data flows between the plan and the platform.
Implementation and Plan Document Considerations
Implementation requires adding a reference to the marketplace in existing member resources. No technical integration is involved. The marketplace operates alongside existing provider arrangements without requiring TPA renegotiation or modification to existing plan infrastructure.
Plan Document Options
Two positioning approaches exist. The first treats the marketplace as an informational resource listed in member materials without any plan-document change. Members access the directory like any other health-related resource. The second formally recognises international care as a covered benefit through a plan-document amendment, which may support stop-loss carrier consideration and plan-level cost-sharing adjustments. This is typically a straightforward addition to the out-of-network or voluntary-benefit section. Many plan sponsors begin with the first approach.
What a Lightweight Agreement Covers
Where counsel requires a written agreement, Sylk Health provides one covering basic representations, indemnification, and scope. It doesn't create data-sharing obligations, clinical responsibilities, or integration requirements. There are none to create.
Steps to make the directory available to plan members:
- 1Review the marketplace directory and pricing data
- 2Decide on plan-document language (simple amendment for formal benefit recognition, or list as informational resource)
- 3Execute a lightweight agreement where counsel requires it
- 4Add the directory to member resources (intranet, benefits portal, or direct link)
- 5Members search, compare, and book consultations independently
- 6No eligibility files, minimal data footprint, no ongoing administration
Utilisation Patterns
According to Mercer's 2022 National Survey, 44% of large employers offer or plan to offer some form of medical travel benefit. Domestic COE programmes at Walmart and Lowe's document annual utilisation rates of approximately 0.3% of the workforce. The top 1% of claimants drive 28% of total plan costs (WTW, 2025). The relevant utilisation metric isn't mass adoption but whether the 8-12 members per 1,000 facing high-cost elective procedures have access to published international pricing before committing to domestic options.
The provider-funded model (no cost to the plan sponsor) means the utilisation threshold for positive economic impact is effectively zero. The pricing data also functions independently as an external reference point when plan fiduciaries evaluate the reasonableness of domestic procedure costs.
US vs International Pricing: Published Rates by Procedure Category
The following table presents published pricing at JCI or equivalent nationally accredited international facilities alongside US commercial pricing for the same procedure categories. International prices represent standard rates at facilities operating profitably. These aren't negotiated discounts or promotional arrangements. International hospitals publish pricing willingly as a competitive mechanism; no mandate equivalent to US Transparency in Coverage rules was required to produce this data.
| Procedure | US Commercial Price | International Price Examples | US Source | Int'l Source |
|---|---|---|---|---|
| Coronary Artery Bypass (CABG) | $57,240 - $89,094 | India $7,900 | Spain $10,734 | Turkey $13,900 | iFHP 2024, JAHA 2024, Trilliant 2025 | iFHP 2024 |
| Hip Replacement (Total) | $28,167 - $50,564 | India $7,200 | Spain $6,623 | Turkey $13,900 | Trilliant 2025, World Population Review 2025 | iFHP 2024, World Population Review 2025 |
| Spinal Fusion (Single Level) | $80,000 - $150,000 | Thailand $9,500 | India $10,300 | Mexico $15,400 | PLOS ONE 2024 / HCUP NIS | iFHP 2024 |
| Knee Replacement (Total) | $35,000 - $50,564 | India $6,600 | Turkey $10,400 | Thailand $14,000 | Trilliant 2025, KFF/CostHelper | iFHP 2024, World Population Review 2025 |
| Heart Valve Replacement | $71,312 | India $8,000 - $15,000 | Turkey $17,200 | Thailand $33,200 | AHA Circulation 2024 | iFHP 2024, OECD Health at a Glance 2025 |
| Bariatric Surgery (Gastric Bypass) | $20,000 - $35,000 | Turkey $2,150 - $6,500 | India $4,500 - $7,000 | Mexico $5,490 | ASMBS, ACS 2024 | iFHP 2024, World Population Review 2025 |
| Hysterectomy | $12,533 - $15,000 | India $2,700 - $3,200 | Mexico $4,900 - $5,500 | CostHelper 2024 | World Population Review 2025 |
| Prostatectomy (Radical) | $34,720 | India $4,500 - $7,500 | Mexico $5,565 - $8,000 | CostHelper 2024 | World Population Review 2025 |
US commercial prices are drawn from published price transparency data (Trilliant Health 2025, Turquoise Health, JAHA 2024), the iFHP 2024 International Healthcare Cost Comparison Report, and the RAND Corporation Hospital Price Transparency Study (Round 5.1, 2024). International prices are from the iFHP 2024 report, World Population Review 2025, and OECD Health at a Glance 2025.
Actual savings depend on the provider selected, individual case complexity, and existing coverage. Published international prices represent facility and surgeon fees; total episode cost (including travel, lodging, companion expenses, and any domestic follow-up care) varies by destination and individual circumstances. Trilliant Health found up to 9-fold variation for the same procedure across US hospitals. Sylk Health doesn't set, verify, or guarantee provider pricing.
JCI Accreditation and International Quality Standards
What JCI Accreditation Covers
JCI accreditation is an international hospital quality certification from the Joint Commission International, the same body that accredits the majority of US hospitals. JCI evaluates hospitals against more than 1,400 patient safety and quality standards covering clinical care, infection control, medication management, facility safety, patient rights, and governance. Over 1,100 hospitals in more than 70 countries hold JCI accreditation as of 2026. Reaccreditation requires on-site evaluation every three years.
In markets with rigorous national systems, such as China's 3A tertiary hospital classification, Sylk Health also lists providers meeting equivalent national standards. JCI accreditation isn't a Sylk Health endorsement. It's an independent accreditation body with a 25-year track record.
Clinical Evidence from International Registries
A 2025 systematic review of 14 peer-reviewed studies, published in PLoS One (Vuohijoki et al., 2025 (opens in new tab)), found JCI accreditation consistently associated with medication error reductions of 57-61%, improved infection control compliance, and stronger documentation practices. A longitudinal study in BMJ Open (Devkaran et al., 2019 (opens in new tab)) showed quality compliance at JCI-accredited hospitals rising from 89% to over 97% across successive accreditation cycles over eight years.
The Commonwealth Fund's Mirror, Mirror 2024 (opens in new tab) study ranked the US last among 10 high-income countries in overall health system performance, despite ranking second in clinical care quality. Clinical quality exists outside the US. OECD data across 38 member nations confirms that 30-day post-surgical mortality has declined in nearly every country over the past decade.
International JCI-accredited hospitals perform high volumes of complex procedures. Outcome data is published by the hospitals themselves and by international clinical registries. The Chinese Cardiac Surgery Registry, for example, covers 74+ tertiary hospitals and provides population-level outcome data cited increasingly in international cardiology literature.
The evidence base has real limitations. A systematic review by Brubakk et al. (2015, BMC Health Services Research) (opens in new tab) found only one randomised controlled trial meeting rigorous criteria, and concluded that RCT evidence for accreditation's effectiveness remains limited. The observational evidence is positive. The evidence base is still developing. Orthopaedic, bariatric, and oncology outcome data from international centres varies by institution and by country.
Sylk Health provides the information that exists (accreditation status, provider-reported volume and wait times) and enables patients and their physicians to make informed decisions. JCI-accredited institutions meet a defined international standard. For specific high-volume procedures at specific high-volume centres, the published clinical evidence is substantial. Browse accredited providers by specialty
Sylk Health is a marketplace that provides access to a directory of JCI or equivalent nationally accredited international healthcare providers. Sylk Health does not provide medical care, coordinate clinical services, or endorse specific providers. All providers listed on the marketplace are independent. Clinical outcomes are the responsibility of the treating provider. Patients should consult their own physicians before making treatment decisions. Provider-listed prices are published by the providers themselves. Sylk Health does not set, verify, or guarantee provider pricing. Actual costs may vary based on individual case complexity, provider selection, and treatment requirements.
Revenue Model and Cost Structure
Providers pay Sylk Health a commission on completed treatment. The commission is drawn from provider revenue and is not added to the member's price. No fee is charged to the plan sponsor, carrier, member, or referring consultant. No subscription, per-member charge, implementation fee, or contract is required. The marketplace can be made available to plan members by including a reference in existing member resources.
Brokers and affiliates who refer plan clients receive a portion of that commission, paid from Sylk Health's share. It's never an additional cost to the plan, the member, or the employer. Broker compensation is disclosed to the employer as part of the broker agreement.
ERISA Regulatory Framework
General information about recent legal and regulatory developments. Sylk Health isn't an ERISA fiduciary and doesn't provide legal or fiduciary advice. Plan administrators should consult their own ERISA counsel on plan-specific implications.
Post-Stern: Plan Design as Settlor Function
In March 2026, the Southern District of New York ruled in Stern v. JPMorgan Chase & Co. (opens in new tab) that plan design decisions, including which provider directories to make available to members, are settlor functions, not fiduciary functions under ERISA. This district court ruling applied the established settlor/fiduciary distinction to the provider-directory context, though the boundaries of settlor function doctrine remain fact-intensive and subject to ongoing litigation.
Separately, the prohibited transaction claim under ERISA Section 406 survived. Following Cunningham v. Cornell University (SCOTUS, 2025) (opens in new tab), the burden of proving compensation reasonableness now falls on the service provider, not the plaintiff.
Tiara Yachts Inc. (6th Circuit, 2025) (opens in new tab) held that TPAs exercising discretionary authority over plan assets are functional fiduciaries, and that causing a plan to overpay for medical claims can constitute a fiduciary breach.
In April 2026, DOL Field Assistance Bulletin 2026-01 (opens in new tab) reinforced that ERISA is a law of process, not results. Fiduciaries who document a thorough cost evaluation process are protected, even when they make unconventional plan design choices.
155 ERISA fiduciary class-action lawsuits were filed in 2025, with 98 targeting defined contribution plans and 39 targeting health plans (Encore Fiduciary, 2025). A new wave of voluntary benefits class actions extends fiduciary scrutiny to every category of plan spending.
Marketplace Precedent: Healthcare Directory Platforms
HHS-OIG issued two Advisory Opinions (AO 19-04 and AO 23-04) (opens in new tab) evaluating Zocdoc's healthcare directory and booking platform, finding that while the model implicates the Anti-Kickback Statute, it doesn't warrant enforcement action when fees are set in advance at fair market value, aren't tied to referral volume, and the platform doesn't influence patient choices. In Sisselman v. Zocdoc (2d Cir. 2025), the Second Circuit affirmed dismissal, finding Zocdoc's reliance on these OIG opinions demonstrated good faith. Advisory opinions are issued to the requesting party and the AKS applies to federal healthcare programmes; self-funded ERISA plans operate in a different regulatory context. The structural parallels (directory model, provider-funded fees, no patient steering) are noted as market context, not as direct regulatory cover.
International Price Benchmarks and Compensation Reasonableness
In 2026, Congress, the DOL, and the FTC each took action to increase healthcare cost transparency, including new PBM disclosure requirements under ERISA Section 408(b)(2), DOL proposed regulations requiring advance fee disclosures from PBMs, and the FTC's structural pricing transparency requirements in the Express Scripts settlement.
The regulatory direction is clear: plan fiduciaries are expected to evaluate whether the prices their plans pay, and the fees their intermediaries charge, are reasonable. International price benchmarks from JCI or equivalent nationally accredited providers provide one external reference point for that evaluation. Sylk Health provides the pricing data. Plan fiduciaries and their advisors determine how to use it.
Legal information, not legal advice. The developments described on this page are provided for informational purposes only. This content does not constitute legal advice, fiduciary guidance, or a recommendation regarding any specific plan's arrangements. ERISA compliance depends on the specific facts of each plan. Plan fiduciaries should consult qualified ERISA counsel before making decisions about plan design, intermediary compensation, or benefit offerings. Sylk Health is a marketplace that provides access to a directory of JCI or equivalent nationally accredited international healthcare providers.
Frequently Asked Questions
Sylk Health has no role in the member's care. Sylk Health operates a marketplace where JCI or equivalent nationally accredited international providers list their procedures, prices, and consultation availability. Members browse the directory, compare options, and book consultations directly with providers. From that point, the relationship is between member and provider. Sylk Health doesn't coordinate care, arrange logistics, manage clinical decisions, or sit between the patient and the hospital in any capacity.
All medical procedures carry risk, whether performed domestically or internationally. The treating provider is responsible for complications arising from treatment, consistent with their own clinical protocols and the terms of the patient-provider agreement. Sylk Health doesn't provide post-operative care, maintain a US clinical presence, or manage clinical follow-up.
Members should discuss complication management directly with the treating provider before proceeding, including what happens if they return to the US before completing follow-up. Members should also consult with their US-based physicians about continuity of care.
Many members who travel for international procedures independently purchase complication coverage (sometimes called international medical travel insurance), a standalone product covering follow-up care costs. These policies are available from several international health insurers and are purchased directly by the member.
Sylk Health's data record for each user consists of an auto-assigned ID, an email address, and the name of the procedure for which a consultation was requested. This minimal data footprint is designed to fall below the PHI threshold under HIPAA. No names, demographics, diagnosis codes, insurance identifiers, or clinical records are collected. Based on this data posture, a BAA is not expected to be required. Employers should confirm with their own privacy counsel.
The marketplace sits alongside existing arrangements as an additional resource members can access voluntarily. No TPA renegotiation, no modification to existing provider arrangements, no claims adjudication change. If a plan elects to formally recognise international care as a covered or reimbursable benefit, that requires a plan-document amendment. Many plans start by listing the marketplace in member materials without any plan-document change.
ERISA doesn't prohibit plan sponsors from making international providers available to members. Plan design choices, including which provider directories are accessible, are generally treated as settlor functions rather than fiduciary functions under established case law, as applied in Stern v. JPMorgan (SDNY, 2026). The characterisation is fact-specific and plan administrators should consult with their own ERISA counsel on plan-document language and benefit design.
Implementation involves adding a link, a paragraph, or a section to the materials plan members already receive: benefit guides, member portals, open-enrolment communications. No technical integration, no eligibility file, no API connection, no IT project. Where counsel requires a written agreement, Sylk Health provides one covering standard representations and indemnification. The process from initial review to member access typically takes less than 30 days.
JCI accreditation evaluates hospital-level quality systems against more than 1,400 measurable standards. For surgeon-level and procedure-level outcome data, plan administrators and members can request outcome information directly from the provider during the consultation process. Outcome data is published by international hospitals and by international clinical registries. Sylk Health provides the consultation booking; clinical evaluation is between the patient and the provider.
Nothing. No platform fee, subscription, per-member charge, implementation fee, or ongoing cost. Sylk Health is paid by providers on completed treatment. The commission comes from the provider's revenue and isn't added on top of what the member pays.
A self-insured (self-funded) employer is a company that pays employee healthcare claims directly from its own funds rather than purchasing a fully-insured group health policy from a carrier. Self-insured employers typically purchase stop-loss insurance to cap catastrophic exposure and use a third-party administrator (TPA) to process claims. Approximately 65% of covered workers in the US are in self-insured plans.
Published Pricing: 1,954 International Procedures
Pricing data from JCI-accredited international facilities, organised by procedure category and country.
Sylk Health operates an online marketplace listing JCI or equivalent nationally accredited international healthcare providers. Sylk Health is not a healthcare provider, insurance company, health plan, or clinical service. Sylk Health does not provide medical advice, coordinate care, arrange travel, or manage clinical outcomes. All providers listed on the marketplace are independent entities. Patients contract directly with providers. Provider-listed prices are published by the providers themselves and may change without notice. Sylk Health does not set, verify, or guarantee provider pricing. Actual costs depend on individual case complexity, provider selection, and treatment requirements. Content on this page is for informational purposes only and does not constitute medical, legal, actuarial, or fiduciary advice. Plan administrators, carriers, and healthshare ministries should consult their own qualified advisors before making decisions based on information presented here. Sylk Health has no affiliation with any third-party organisation referenced on this page unless explicitly stated.